According to the external media review, AGI is expected to improve the efficiency of drug research and development and even to help combat more diseases, but this goal is still far from being applied. According to the article, AI does show speed advantages in molecular screening, data analysis and clinical design, but “faster” does not mean “quick cure of disease”.
AI's speeded up in drug detection.
It was mentioned that traditional drug discovery usually involves repeated error around genes, proteins and molecular structures, long research and development cycles and high costs, and many breakthroughs are accidental. AI has the value of being able to handle data sizes that are far beyond artificial capacity and to find more viable alternatives from complex protein and molecular relationships.
The author cites academic research that AI is shifting part of the process that relied on “lucky” in the past to a more structured form of screening. Such systems allow for a faster identification of potential drug combinations and also contribute to more efficient detection of commercially available candidate drugs.
Cost and cycle are expected to decline
Another cited study found that AI Auxiliary Drug Development has brought efficiency gains in patient recruitment, data processing and clinical trial design, thus reducing some of the development costs and time. This is particularly important for the pharmaceutical industry, as the marketing of new medicines often requires years of investment and high levels of funding.
If AI can reduce resource consumption of R & D in a sustained manner, then theoretically it may also ease some of the price pressures. According to the article, this is also one of the important reasons why the market has maintained a high level of interest in AGI’s medical prospects.
Clinical trials and data remain bottlenecks
At the same time, however, it was stressed that even if AGI continued to improve its capacity, it could not circumvent the actual clinical trial constraints. At the end of the day, it was still true patients, ethical review and long-term observation, which were difficult to reduce.
The authors also note that the effectiveness of the AI system depends on the quality and completeness of the input data, while existing medical knowledge and clinical data are still scattered across institutions and systems. AI can help to integrate information, but it is still a prerequisite for adequate data access and clear guidelines for use.
Policy synergies remain to be advanced
The article concludes that more consistent policy arrangements and security constraints, in addition to technological advances, are required for medical AGI to enter larger applications. The reason for this is that once such systems enter disease treatment and clinical decision-making, the impact is not only on research and development efficiency, but also on patient safety and responsibility.
Overall, this comment does not deny the AGI contribution to medical research and development, but the central judgement is that AI is more likely to be an accelerator for drug discovery and experimental design than a direct “all diseases” in the short term.